

BIOMARKERS (NON-NEUROIMAGING)

Associations between CSF complement factors and biomarkers of amyloid, tau, neurofilament light chain, and α -synuclein in AD, DLB, and PD

Marianna Rizzo¹ | Charlotte E. Teunissen² | Frederic Brosseron³ | Sandra Kuhs³ | Gwendlyn Kollmorgen⁴ | Henrik Zetterberg^{5,6,7,8} | Kaj Blennow^{9,10} | Rejko Krüger^{11,12,13} | Sara B. Gomes Fernandes¹² | Dag Aarsland^{14,15} | Olga Borejko¹⁴ | Davit Chokoshvili¹⁶ | Wiesje M. van der Flier^{17,18} | Afina W. Lemstra¹⁷ | Betty M. Tijms¹⁷ | Gabor C Petzold^{19,20} | Annika Spottke^{3,21} | Giovanni B. Frisoni^{22,23} | Kathrin Brockmann^{24,25} | Thomas Gasser^{24,25} | Tormod Fladby^{26,27} | Marianne Wettergreen^{26,27} | Frank Jessen^{28,29,30} | Emrah Düzel^{31,32} | Günter U Höglinger^{33,34} | Claire Chevalier^{22,23} | Rajaraman Krishnan³⁵ | Pieter Jelle Visser^{1,17,36} | Stephanie J. B. Vos¹ | on behalf of the IMI EPND consortium

¹Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, Netherlands²Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands³German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany⁴Roche Diagnostics GmbH, Penzberg, Germany⁵Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom⁶Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA⁷Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Gothenburg, Sweden⁸Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Västra Götaland län, Sweden⁹Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden¹⁰Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden¹¹Transversal Translational Medicine, Luxembourg Institute of Health, Strassen, Luxembourg¹²Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg¹³Parkinson Research Clinic, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg¹⁴Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom¹⁵Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Stavanger, Norway¹⁶Luxembourg National Data Service, Esch-sur-Alzette, Luxembourg¹⁷Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2025 The Alzheimer's Association. *Alzheimer's & Dementia* published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

¹⁸Department of Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, North Holland, Netherlands

¹⁹German Center for Neurodegenerative Diseases (DZNE), Bonn, NRW, Germany

²⁰Division of Vascular Neurology, Department of Neurology, University Hospital Bonn, Bonn, NRW, Germany

²¹Department of Neurology, University of Bonn, Bonn, Germany

²²Memory Clinic, Geneva University Hospitals, Geneva, Switzerland

²³Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland

²⁴Hertie Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany

²⁵German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany

²⁶Department of Neurology, Akershus University Hospital, Lørenskog, Norway

²⁷Institute of Clinical Medicine, University of Oslo, Oslo, Norway

²⁸Department of Psychiatry, University of Cologne, Medical Faculty, Kerpener Strasse 62, Cologne, Germany

²⁹Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany

³⁰German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany

³¹German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany

³²Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Sachsen Anhalt, Germany

³³German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Strasse 17, 81377, Munich, Germany

³⁴Department of Neurology, University Hospital, LMU Munich, Munich, Bavaria, Germany

³⁵Sanofi, Cambridge, MA, USA

³⁶Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden

Correspondence

Marianna Rizzo, Alzheimer Center Limburg,
School for Mental Health and Neuroscience,
Maastricht University, Maastricht,
Netherlands.
Email: marianna.rizzo@maastrichtuniversity.nl

Abstract

Background: While evidence suggests complement system involvement in Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), and Parkinson’s disease (PD), its association with disease biomarkers remains unclear. We investigated the relationship of complement factors with amyloid, tau, NfL, and α -synuclein in CSF in AD, DLB, PD, and controls.

Method: We included 321 individuals with AD, DLB, PD, and controls from 6 centers of the EPND study. CSF A β 42/40, *p*-tau181, NfL, and α -syn were centrally measured using NeuroToolKit (Roche Diagnostics), and 14 CSF complement factors using Milliplex (Merck KGaA). Controls were defined as normal cognition and normal A β 42/40, whereas AD as abnormal A β 42/40 without meeting clinical criteria of DLB or PD. Linear regression models adjusted for age and sex were used. Associations were post-hoc compared between individuals with low(≤ 23), intermediate(24-27), and high(≥ 28) MMSE scores.

Result: Sample characteristics are presented in Table 1. Lower A β 42/40 levels were associated with lower levels of 7 complement factors in controls and with higher C1q and C2 levels specifically in AD (Figure 1, Figure 2). No associations of A β 42/40 with complement were found in DLB and PD. Higher *p*-tau181 levels were associated with increased levels of 7 complement factors in controls and 6 in AD, and showed fewer associations in DLB and PD. The strength of *p*-tau181 associations with complement was similar across groups. Higher NfL levels were widely associated with higher complement factor levels in controls (13) and AD (12), and less in PD (6) and DLB (4). Higher α -syn levels were broadly associated with higher complement factor levels in

AD (13), controls (12), and DLB (12), but only minimally in PD (1). The strength of these NfL and α -syn associations with complement was not disease-specific. Conversely, compared to all groups, in PD higher α -syn levels were associated with lower C5, C5a, C9, factor-I and properdin levels. Individuals with intermediate MMSE scores largely drove the associations of α -syn with complement in AD. MMSE level did not clearly impact other associations.

Conclusion: CSF complement factors were associated with amyloid, tau, NfL, and α -synuclein, suggesting complement system involvement in several neurodegenerative diseases. Complement showed disease-specific associations with amyloid in AD and α -synuclein in PD.

Table 1. Sample characteristics.

	Control	AD	DLB	PD	Total sample
N	47	147	53	74	321
Age	63.7 (9.6) ^{B,C}	69.3 (8.3) ^{A,D}	69.6 (6.7) ^{A,D}	62.7 (10.2) ^{B,C}	67.0 (9.2)
Female sex (%)	14 (30%)	66 (45%) ^C	9 (17%) ^B	24 (32%)	113 (35%)
Education years	14.6 (3.4) ^{B,C,D}	12.8 (3.4) ^A	11.9 (2.8) ^{A,D}	13.2 (3.5) ^{A,C}	13.0 (3.4)
APOE-ϵ4 carriers (%)	4 (8.7%) ^{B,C}	94 (64%) ^{A,D}	24 (51%) ^{A,D}	16 (25%) ^{B,C}	138 (45%)
MMSE score	29.0 (1.1) ^{B,C}	25.2 (4.0) ^{A,C,D}	23.8 (3.7) ^{A,B,D}	28.5 (1.7) ^{B,C}	26.3 (3.7)
MDS-UPDRS-III score	2.9 (2.6) ^{C,D}	6.0 (7.9) ^{C,D}	19.8 (15.2) ^{B,D}	31.3 (15.0) ^{A,B,C}	25.5 (16.9)
Aβ42/40	0.07 (0.01) ^{B,C}	0.03 (0.01) ^{A,C,D}	0.05 (0.02) ^{A,B,D}	0.07 (0.01) ^{B,C}	0.05 (0.02)
P-tau181	16.2 (5.3) ^{B,C}	28.6 (13.5) ^{A,C,D}	19.5 (6.5) ^{A,B,D}	15.5 (5.7) ^{B,C}	22.3 (11.7)
NfL	116.7 (81.3) ^{B,C}	197.3 (189.3) ^{A,D}	212.9 (232.1) ^{A,D}	145.9 (168.7) ^{B,C}	176.2 (183.6)
α-Syn	153.0 (324.1)	145.8 (257.4) ^D	121.4 (103.7)	112.3 (67.9) ^B	135.1 (220.0)
C1q	211.1 (88.1)	213.8 (141.6)	215.8 (94.7)	205.5 (75.3)	211.8 (114.1)
C2	132.2 (95.9) ^C	130.6 (72.3) ^C	177.9 (78.8) ^{A,B,D}	110.4 (45.7) ^C	134.0 (75.1)
C3	4110.3 (2545.0)	3681.8 (2344.1) ^C	5170.2 (3870.0) ^B	4251.7 (3035.2)	4121.7 (2872.0)
C3b	557.7 (710.6) ^B	378.2 (507.2) ^{A,C,D}	805.8 (1318.2) ^B	680.8 (1079.5) ^B	544.8 (875.5)
C4	1663.7 (731.5)	1553.1 (908.7)	1577.1 (738.3)	1584.0 (756.9)	1580.4 (821.1)
C4b	136.3 (82.1)	135.4 (74.8)	150.1 (77.8)	134.5 (81.5)	137.8 (77.8)
C5	52.3 (63.5)	48.6 (94.1) ^{C,D}	63.5 (74.5) ^B	52.2 (50.1) ^B	52.4 (78.2)
C5a	91.9 (95.5)	80.2 (104.9) ^{C,D}	117.7 (121.3) ^B	102.4 (91.6) ^B	93.2 (104.1)
C9	93.4 (90.9)	83.8 (75.4) ^{C,D}	110.9 (69.8) ^B	110.1 (89.4) ^B	95.7 (80.9)
Factor D	29.5 (14.2)	27.9 (13.2) ^C	32.6 (11.3) ^B	29.5 (13.8)	29.3 (13.2)
Factor I	200.5 (134.5)	172.4 (116.9) ^{C,D}	194.1 (85.8) ^B	195.3 (79.7) ^B	185.4 (107.8)
Factor H	671.6 (352.0)	609.7 (460.2)	662.6 (339.4)	640.1 (257.0)	634.5 (385.8)
Factor B	629.1 (409.9) ^B	493.0 (367.1) ^{A,D}	545.5 (269.0)	567.5 (305.0) ^B	538.8 (347.8)
Properdin	7.5 (9.3)	8.4 (30.6) ^{C,D}	8.5 (11.5) ^B	7.0 (4.3) ^B	8.0 (21.6)

The table shows key characteristics of the overall group and of each diagnostic group. Values represent mean (SD) for continuous variables, or N (%) for dichotomous variables. Education years were available for N=314 individuals, APOE- ϵ 4 carriership for N=304, MMSE score for N=310, and MDS-UPDRS-III score for N=104. CSF A β 42/40, p-tau181, NfL, and α -syn levels are expressed in pg/mL, whereas CSF complement factors levels in ng/mL. Differences between groups were tested with ANOVA for continuous variables and Chi-Squared for dichotomous variables. For analyses, all CSF measures were log-transformed, and their outliers were winsorized at ± 3 SD from mean to improve model fits. Unadjusted group comparisons $p < 0.05$ compared to: (A) controls, (B) AD, (C) DLB, (D) PD. CSF A β 42/40, p-tau181, NfL, and α -syn were measured via the NeuroToolKit, a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use (Roche Diagnostics International Ltd, Rotkreuz, Switzerland); all other product names and trademarks are the property of their respective owners. Abbreviations: APOE = Apolipoprotein E, MDS-UPDRS-III = Movement Disorders Society Unified Parkinson Disease Rating Scale Part III.




Figure 1. Associations of complement factors with ATN and α-synuclein markers in CSF in AD, DLB, PD, and controls. The heatmap shows linear associations between levels of complement factors and levels of Aβ42/40, p-tau181, NfL, and α-syn in CSF in AD, DLB, PD, and controls. Red colours represent higher complement factor levels with more abnormal Aβ42/40, p-tau181, and NfL levels, and with higher α-syn levels (positive associations), whereas blue colours represent associations of an opposite direction. White represents lack of statistically significant associations ($p \geq 0.05$). For analyses, all CSF measures were log-transformed, and their outliers were winsorized at ± 3 SD from mean to improve model fits.

